Jim Joyce, co-founder, chairman, and CEO of Sigyn Therapeutics discusses the development of Sigyn Therapy, the company’s blood purification technology to overcome the limitations of drugs and other devices to treat Cytokine Storm induced inflammatory conditions that lead to sepsis. He explains the relationship between Cytokine Storm and COVID and how this blood purification technology is an […]

STRO-002 is a folate receptor alpha-targeting antibody drug conjugate for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy. Sutro Biopharma has been granted FDA Fast Track Designation for STRO-002, a folate receptor alpha-targeting antibody drug conjugate indicated for […]

The FDA granted fast track designation to STRO-002 for treatment of certain women with advanced gynecologic cancer. The designation applies to use of the agent with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who received one to three prior lines of systemic therapy.